Hong Kong PR

香港，2025年9月23日 - (亞太商訊 via SeaPRwire.com) - 大洋集團控股有限公司（「大洋集團」或「集團」；股份代號：1991.HK）欣然宣佈，為把握Web4.0發展機遇，進一步推進其AI與數字化轉型戰略，公司目前正考慮一項潛在供股計劃，計劃募集資金用於AI數字人的研究與開發、建立真實世界資產（「RWA」）的底層資產組合及鏈上方案構建、購買戰略性數字資產如以太坊（「ETH」）等加密貨幣作為新業務所需儲備等，與集團向Web4.0戰略轉型以及RWA生態佈局的前期工作相關。此潛在供股計劃可望為集團於8月所宣佈向助力企業或機構進行之AI與數字化轉型業務發展之戰略方向提供財務支持，比如在建立核心數字資產池、加速AI數字人技術研發及深化RWA生態佈局等方面。同時，潛在供股可為集團帶來新資金及資源以堅實財務基礎，賦能大洋集團緊抓其面向的教育、遊戲、大健康三大萬億賽道行業的數字化轉型所帶來的長遠機遇。大洋集團主席施琦女士表示：「是次潛在供股計劃對於大洋集團邁向數字經濟新時代有着至關重要的積極正面意義。我們正經歷資本革新、到技術革新、再到業態革新的脫變過程，恰恰與我們早前公佈的轉型藍圖相輔相成。相信潛在供股的機會將使我們搶佔Web4.0發展先機，加快RWA領域佈局，未來有望拓展包括AI數字人服務付費、數字人IP交易、RWA生態服務在內等新收入來源。我們感謝股東一直以來的支持，並堅信此符合戰略規劃的舉動將為股東創造長期且可觀的回報。」關於大洋集團控股有限公司(股份代號: 1991)大洋集團控股有限公司（股票代號：1991）成立於 1991 年，2007 年在香港聯合交易所有限公司成功上市，是一家兼具三十年産業積澱與前瞻數字視野的多元化企業。自創立以來，集團早期聚焦矽膠輸入設備領域，專業設計及製造用於消費電子裝置、計算機、筆記本電腦、手提電話及汽車周邊産品的核心部件，憑藉高度整合的生産體系、嚴苛的品質管控與技術創新能力，贏得全球眾多知名品牌客戶的長期信賴，奠定了堅實的産業根基。隨着全球數字化轉型浪潮的深化，大洋集團敏銳洞察數字經濟時代的戰略機遇，果斷啓動向 Web4.0 領域的全方位戰略轉型，以「擁抱技術變革、重構價值生態」為核心方向，精準錨定人工智能（AI）、真實世界資産（RWA）代幣化及香港政策生態三大核心驅動力，致力於打通 「數據 — 資産 — 價值」 的轉化鏈路，開啓從傳統製造向數字經濟領航者的跨越。當前，大洋集團正以 Web4.0 戰略轉型為新起點，聚焦教育、游戲、大健康三大萬億賽道，致力於成為亞太地區 AI 與 RWA 雙賽道的領先企業，為全球投資者、合作夥伴及個人用戶提供高效的價值增長生態，持續推動全球數字經濟高質量發展，寫下從「産業深耕者」到「數字生態構建者」的全新一頁。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, Sept 23, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 22 September 2025, the Group through its subsidiaries entered into two separate exclusive Collaboration Agreements (the “Agreements”) with Chongqing Genrix Biopharmaceutical Co., Ltd. (“Genrix Bio”) for two Class 1 therapeutic biological products, Vecantoxatug Injection (GR2001, “Vecantoxatug”) indicated for passive immunization against tetanus and Silevimig Injection (GR1801, “Silevimig”) indicated for passive immunization following suspected rabies virus exposure, respectively. In accordance with the Agreements, the Group has obtained exclusive commercialization rights for these two products in mainland China and exclusive licensing rights for the rest of the Asia-Pacific region, the Middle East and North Africa. The collaboration terms respectively extend until ten years after these two products receive their marketing approvals in Mainland China (the “Initial Term for each Product”). Unless terminated or dissolved under the terms set forth in the Agreements, the Agreements will automatically renew for successive ten-year periods upon expiration of the Initial Term for each Product.Vecantoxatug is a passive immunization agent with an excellent safety profile, which delivers superior protection compared with human tetanus immunoglobulin (HTIG), providing rapid and durable immune defense for patients. Its Phase III clinical trial for passive immunization against tetanus successfully met the primary efficacy endpoint. In May 2024, Vecantoxatug was designated Breakthrough Therapy by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). On 22 May 2025, its New Drug Application (NDA) was formally accepted by the CDE.Silevimig is the world’s first recombinant, fully human bispecific antibody against rabies virus (RABV) targeting epitope I and/or epitope III of the rabies virus glycoprotein, developed in accordance with the World Health Organization (WHO) recommended “cocktail” therapeutic option targeting distinct antigenic sites. It can be manufactured at scale with standardized, and also demonstrates broad neutralization, low immunogenicity, minimal interference with vaccine-induced active immunity, and controlled production cost. On 14 January 2025, its NDA for use in adults requiring passive immunization following suspected rabies virus exposure was formally accepted by CDE. In addition, in July 2025, the NMPA approved the clinical trial application for Silevimig in children and adolescents aged 2 to <18 years requiring passive immunization following suspected rabies virus exposure. This Phase III clinical trial is currently in progress.CMS has always been committed to deploying innovative products with clinical value and differentiated advantages. The market for tetanus and rabies passive immunization remains substantial, yet existing passive immunization products are constrained by safety and accessibility concerns. If approved, Vecantoxatug and Silevimig will provide new preventive and therapeutic options of passive immunization for patients following tetanus and rabies exposure. Additionally, they will synergize with the Group’s existing products in expert networks and market resources, bringing benefit to patients.More information about Vecantoxatug and TetanusVecantoxatug is a recombinant humanized monoclonal antibody against tetanus neurotoxin (TeNT), which is self-developed by Genrix Bio. Vecantoxatug binds to the fragment C domain of the TeNT heavy chain (TeNT-Hc). TeNT is an about 150 kDa single-chain protein that undergoes post-translational modification to form an active toxin composed of heavy and light chains. By specifically binding TeNT-Hc, Vecantoxatug effectively blocks toxin entry into neurons, providing passive immunization. The patent for Vecantoxatug has been granted in China.Tetanus is an acute and specifical infection caused by Clostridium tetani (C. tetani) entering the body through wounds. It affects individuals across all age groups and, in the absence of medical intervention, is almost universally fatal-particularly among infants and the elderly. Even with active treatment, global mortality remains as high as 30-50%, with an estimated 500,000 to 1,000,000 cases reported annually worldwide[1].C. tetani is ubiquitous in soil and the environment, and is also present in the intestines of mammals. As the pathogen invades through skin or mucosal injuries, causing the acute and specifical infection, prevention remains the most effective strategy. Currently available passive immunization agents, commonly known as tetanus shot, - tetanus antitoxin (TAT), equine-derived tetanus immunoglobulin (F(ab’)2), and human tetanus immunoglobulin (HTIG) - face notable limitations in safety and accessibility[2], including risks of allergic reactions, potential infectious pathogen transmission, and limited availability. Consequently, there remains a pressing clinical need for new preventive and therapeutic options. Vecantoxatug is able to provide greater protection than HTIG, while demonstrating excellent safety, tolerability, and low immunogenicity. With enhanced controllability and accessibility, Vecantoxatug has the potential to offer patients an advanced preventive and therapeutic option.More information about Silevimig and RabiesSilevimig is a recombinant, fully human bispecific antibody against rabies virus, which is self-developed by Genrix Bio. It targets the viral envelope glycoprotein (G protein) of RABV and blocks its interaction with host receptors by binding to epitopes I and/or III. Through this mechanism, Silevimig prevents RABV from invading neural tissue prior to the establishment of full protection by active rabies vaccination, thereby helping to prevent rabies infection. Silevimig’s molecular design is consistent with the recommendations of the WHO for anti-RABV antibody development, which emphasize the use of “cocktail” combinations of monoclonal antibodies targeting distinct antigenic sites to ensure broad effectiveness across different viral strains and genotypes. The patent for Silevimig has been granted in China.In a Phase III clinical trial for post-exposure passive immunization in adults, Silevimig met its primary efficacy endpoint, demonstrating non-inferior protective efficacy compared with human rabies immunoglobulin (HRIG), the currently most used passive immunization product in China. The study confirmed that Silevimig provides immediate protection during the early stages of rabies virus exposure without compromising the active immune response induced by vaccination.Rabies is an acute zoonotic disease caused by RABV, clinically characterized by hydrophobia, aerophobia, pharyngeal muscle spasms, and progressive paralysis[3]. With a case-fatality rate approaching 100%, it is one of the deadliest diseases worldwide. At present, there is no proven treatment for rabies once clinical symptoms appear. Standardized Post-Exposure Prophylaxis (PEP), comprising wound care, vaccination, and passive immunization administered as needed, remains the most effective rabies prevention strategy[4]. As vaccine-induced antibodies require 1–2 weeks after the first dose of vaccine injection, to reach protective levels (≥0.5 IU/mL), passive immunization provides immediate coverage during this high-risk window[3]. According to the the National Regulation for the Rabies Exposure Prophylaxis (2023 Edition), patients with Category III exposure and those with severe immunodeficiency and Category II exposure should receive passive immunization at the same time as the first dose of rabies vaccine[5]. In China, more than 40 million people are exposed to rabies annually, of whom approximately 40% (16 million) fall under Category III exposure[3]. However, due to factors such as limited awareness, high cost, and restricted accessibility, only about 15% of Category III cases receive passive immunization[3].Currently approved passive immunization options in China include human rabies immunoglobulin (HRIG) and equine rabies antiserum (ERA), both of which provide immediate protection by preventing viral entry into neural tissue. HRIG must be sourced from repeatedly immunized healthy donors, making it difficult and costly to obtain. And it is associated with potential risks of blood-borne infections (e.g., HIV, hepatitis B, hepatitis C). ERA, being a heterologous protein, is prone to adverse reactions such as serum sickness and anaphylactic shock[3]. Beyond HRIG and ERA, only two rabies antibody products have been approved in China to date. Silevimig is the world’s first recombinant, fully human bispecific antibody for passive immunization against rabies, which is consistent with the WHO recommended “cocktail” approach. Its approval is expected to provide patients with broad and robust protection.About GENRIX BIOGenrix Bio (Stock Code: 688443), founded in 2015, is an innovative biopharmaceutical company driven by advanced antibody drug discovery technology to address critical clinical needs. Genrix Bio is committed to the development of monoclonal and bispecific antibodies for autoimmune diseases, infectious diseases, and oncology. Its capabilities span across antibody molecular discovery, process development and quality research, clinical trials, and large-scale commercialization. Learn more about Genrix Bio and its products at https://www.genrixbio.com/About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.Reference:1. China Trauma Rescue and Treatment Association. Peking University Trauma Medicine Center. Chinese expert consensus on tetanus immunization[J]. Chinese Journal of Surgery,2018,56(3):161-167. DOI: 10.3760/cma.j.issn.0529-5815.2018.03.0012. Members of the Emergency Surgery Committee of Chinese College of Emergency Physicians, Members of the Emergency Medicine Committee of the People's Liberation Army, Beijing Society for Emergency Medicine, et al. Expert consensus on prophylaxis, diagnosis and management of tetanus among adults[J]. Journal of Clinical Emergency, 2018, 19(12):801-811. DOI: 10.13201/j.issn.1009-5918.2018.12.0013. Chinese Center for Disease Control and Prevention. Technical Guidelines for Human Rabies Prevention and Control (2016). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525420231910.pdf4. Yin Wenwu, Wang Chuanlin, et al. Expert consensus on rabies exposure prophylaxis[J]. Chinese Journal of Preventive Medicine, 2019,53(7):668-679. DOI:10.3760/cma.j.issn.0253-9624.2019.07.0045. Chinese Center for Disease Control and Prevention. The National Regulation for the Rabies Exposure Prophylaxis (2023 Edition). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525421817465.pdfCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳，2025年9月23日 - (亞太商訊 via SeaPRwire.com) - 康哲藥業控股有限公司（「康哲藥業」）欣然宣佈，於2025年9月22日，通過其附屬公司與重慶智翔金泰生物製藥股份有限公司（「智翔金泰」）就兩款1類治療用生物製品分別簽訂獨家合作協議（「協議」），分別為用於破傷風的被動免疫適應症的唯康度塔單抗（GR2001）注射液（「唯康度塔單抗注射液」）以及用於疑似狂犬病病毒暴露後的被動免疫適應症的斯樂韋米單抗（GR1801）注射液（「斯樂韋米單抗注射液」）。根據協議，康哲藥業獲得上述兩款產品在中國大陸的獨家商業化權與除中國大陸之外的亞太地區及中東、北非的獨家許可權，合作期限至兩款產品分別在中國大陸地區獲批上市後十年（各产品的初始期限），各产品的初始期限到期後除非發生協議約定的終止或解除情形，則協議每十年自動延期。唯康度塔單抗注射液是一款安全性佳，且優效於破傷風人免疫球蛋白（HTIG），可為患者提供快速且持久保護的被動免疫製劑。唯康度塔單抗注射液用於破傷風的被動免疫適應症的Ⅲ期臨床試驗達到了主要療效終點。2024年5月，唯康度塔單抗注射液被國家藥品監督管理局（NMPA）藥品審評中心（CDE）納入突破性治療品種名單，其新藥上市申請（NDA）已於2025年5月22日獲得CDE受理。斯樂韋米單抗注射液是全球首款針對狂犬病毒糖蛋白表位Ⅰ和/或III的重組全人源抗狂犬病病毒（Rabies Virus，RABV）雙特異性抗體，符合世界衛生組織（WHO）建議開發的針對不同抗原位點的"雞尾酒式"療法，可大規模標準化穩定生產，並且中和譜廣、免疫原性低、對疫苗主動免疫干擾小、成本可控。2025年1月14日, 其用於成人疑似狂犬病病毒暴露後的被動免疫適應症的NDA獲CDE受理；此外，其針對2歲至18歲以下兒童和青少年疑似狂犬病病毒暴露後的被動免疫適應症的臨床試驗申請已於2025年7月獲得NMPA批准，目前正在進行III期臨床試驗。康哲藥業始終致力於佈局具有臨床價值及差異化優勢的創新產品。破傷風和狂犬病的被動免疫市場廣闊，現有被動免疫製劑在安全性及可及性上存在一定局限性。期待唯康度塔單抗注射液和斯樂韋米單抗注射液的獲批上市，有望為破傷風及狂犬病暴露後患者帶來新的被動免疫防治選擇，並可與康哲藥業在售產品在專家網路與市場資源方面協同，早日惠及廣大患者。關於唯康度塔單抗注射液及破傷風的更多信息唯康度塔單抗注射液是一款由智翔金泰自主研發的重組人源化抗破傷風毒素(Tetanus Neurotoxin, TeNT)的單克隆抗體，作用靶點為TeNT的重鏈C端(TeNT-Hc)。TeNT是一條約150kDa的單鏈蛋白，經過翻譯後修飾，形成由重鏈和輕鏈組成的活性毒素。唯康度塔單抗注射液能特異性結合TeNT-Hc，阻斷其進入神經元細胞，起到被動免疫作用。唯康度塔單抗注射液在中國已取得授權專利。破傷風是由破傷風梭狀芽孢桿菌通過傷口侵入人體引起的急性特異性感染，可發生于任何年齡段，在無醫療干預的情況下，尤其是老年人和嬰幼兒，病死率接近100%。即使經過積極的綜合治療，該病的死亡率在全球範圍仍高達30%至50% [1]。據估計，全球每年約有50萬至100萬例破傷風病例[1]。破傷風梭狀芽孢桿菌廣泛分佈於土壤及環境中，並存在於哺乳動物的腸道中，通過破損的皮膚黏膜侵入人體，引起急性特異性感染，因此破傷風重在預防。目前臨床常用的被動免疫藥物（俗稱"破傷風針"），包括破傷風毒素（TAT）、馬破傷風免疫球蛋白（F(ab’) 2）、破傷風人免疫球蛋白（HTIG），但在安全性和可及性方面存在顯著短板[2]，主要體現在易引起過敏，傳播傳染性病原風險，來源有限等問題，臨床亟須新的防治藥物。唯康度塔單抗注射液可提供優效於HTIG的保護力，展現出優異的安全性和耐受性，免疫原性低，且具備更強的可控性和可及性，有望為患者提供更佳的防治選擇。關於斯樂韋米單抗注射液及狂犬病的更多信息斯樂韋米單抗注射液是一款由智翔金泰自主研發的重組全人源抗狂犬病病毒雙特異性抗體，作用靶點為RABV的包膜糖蛋白（Glycoprotein，G蛋白），通過靶向結合G蛋白表位I和/或III，阻斷其與受體的結合，在狂犬疫苗主動免疫完全發揮保護作用前阻滯病毒對神經的侵染，預防狂犬病。斯樂韋米單抗注射液的分子設計滿足WHO關於抗狂犬病病毒抗體開發的建議——採用針對不同抗原位點的多株單抗組合成"雞尾酒式"組合製劑，以保證對不同病毒株或病毒的不同基因型的有效性。斯樂韋米單抗注射液在中國已取得授權專利。斯樂韋米單抗注射液用於成人疑似狂犬病毒暴露後的被動免疫適應症的III期臨床試驗達到了主要療效終點，研究顯示斯樂韋米單抗注射液與目前我國主要被動免疫製劑狂犬病人免疫球蛋白（HRIG）具有非劣的保護力，在狂犬病毒暴露的早期提供即時保護，且不會對疫苗發揮主動免疫產生不利影響。狂犬病是由RABV感染引起的一種急性人畜共患病，臨床大多表現為特異性恐風、恐水、咽肌痙攣、進行性癱瘓等[3]，病死率幾乎為100%，是世界上最致命的疾病之一。目前對已經出現疾病症狀的狂犬病沒有公認有效的治療方法，規範的暴露後預防（Post-Exposure Prophylaxis，PEP）處置是預防狂犬病的最有效策略[4]。PEP包括傷口處置、疫苗接種、按需注射被動免疫製劑。疫苗誘導產生抗體需要1-2周的時間，在第一針疫苗注射後至機體產生足量抗體（≥0.5IU/ml）之前，被動免疫製劑可為該高風險時段提供即時保護[3]。根據《狂犬病暴露預防處置工作規範(2023年版)》，狂犬病III級暴露後以及嚴重免疫功能缺陷的II級暴露病例應當在第1劑疫苗免疫同時給予被動免疫治療[5]。我國全年狂犬病毒暴露人口數逾4,000萬，其中40%為III級暴露，共1,600萬人[3]。但出於患者認知、價格、可及性等原因，III級暴露者中，僅15%左右接受被動免疫製劑注射[3]。我國被批准上市的被動免疫藥物有狂犬病人免疫球蛋白（HRIG）或馬源抗狂犬病血清(Equine Rabies Antiserum，ERA)，以阻止病毒進入神經組織從而獲得快速保護作用。HRIG需要不斷從加強免疫的健康人群中獲得，來源相對困難，價格昂貴，存在血源感染的潛在風險（如愛滋病，乙肝，丙肝等）；ERA屬於異源蛋白，易導致不良反應（如血清病，過敏性休克等）[3]。除HRIG和ERA外，國內僅有兩款抗狂犬病病毒抗體藥物獲批上市。斯樂韋米單抗注射液是全球首款用於狂犬病被動免疫的重組全人源雙特異性抗體，符合WHO推薦的"雞尾酒式"療法，其上市有望給患者提供多方位保護。關於智翔金泰智翔金泰（股票代碼：688443）成立於2015年，是一家以臨床重大需求為導向，以抗體藥物發現技術為驅動的創新型生物製藥企業。公司聚焦自身免疫性疾病、感染性疾病和腫瘤三大治療領域，持續開發單克隆抗體藥物及雙特異性抗體藥物，擁有從抗體藥物分子發現、工藝開發與質量研究、臨床研究到大規模商業化的抗體藥物全產業鏈佈局。有關智翔金泰及其產品的更多資訊，請訪問其官方網站：https://www.genrixbio.com/。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化，把控產品全生命週期管理的開放式平台型企業，致力於提供有競爭力的產品和服務，滿足尚未滿足的醫療需求。康哲藥業專注於全球首創（FIC）及同類最優（BIC）的創新產品，並高效推進創新產品臨床研究開發和商業化進程，賦能科研成果向診療實踐的持續轉化，造福患者。康哲藥業聚焦專科領域，擁有被驗證的商業化能力，廣泛的渠道覆蓋和多疾病領域專家資源，核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展，以鞏固心腦血管/消化/眼科/皮膚健康業務競爭力，其中皮膚健康業務已成為該細分領域的龍頭企業，帶來專科規模效率。同時，康哲藥業持續深化東南亞及中東區域業務發展，助力高質量持續健康發展。參考文獻/資料1.中國創傷救治聯盟，北京大學創傷醫學中心. 中國破傷風免疫預防專家共識[J]．中華外科雜誌，2018，56（3）：161-167．DOI: 10.3760/cma.j.issn.0529-5815.2018.03.0012.中國醫師協會急診醫師分會, 中國人民解放軍急救醫學專業委員會, 北京急診醫學學會, 等. 成人破傷風急診預防及診療專家共識[J]. 臨床急診雜誌, 2018, 19(12): 801-811. DOI: 10.13201/j.issn.1009-5918.2018.12.0013.中國疾病預防控制中心.《狂犬病預防控制技術指南（2016版）》. https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525420231910.pdf4.殷文武,王傳林等. 狂犬病暴露預防處置專家共識[J].中華預防醫學雜誌,2019,53（7）：668-679. DOI:10.3760/cma.j.issn.0253-9624.2019.07.0045.中國疾病預防控制中心.《狂犬病暴露預防處置工作規範（2023年版）》. https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525421817465.pdf康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣，非廣告用途。本新聞不對任何藥品和醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療信息，請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請，不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制，但康哲藥業並無進行任何說明或保證、明述或暗示，或其他表述，對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述，該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證，存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測，康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Sep 23, 2025 - (ACN Newswire via SeaPRwire.com) – On September 16th, the "Industrial Intelligent Water Saving and Efficiency Promotion Event & GreenTech WateRobot AI Agent 1.0 Ecosystem Launch", hosted by the China Industrial Energy Conservation and Cleaner Production Association, GreenTech Environment Co., Ltd., and Beijing Zhenghe Island Information Technology Co., Ltd., was successfully convened in Beijing.Centered on the theme "AI for Water Freedom", the event brought together nearly 400 industry experts, research institutions, universities, environmental protection enterprises, and financial institutions to witness the launch of the WateRobot AI Agent and explore the new developments in water savings and efficiency brought by AI agents to the industry.(Launch event scene)Wang Xiaokang, President of the China Industrial Energy Conservation and Cleaner Production Association, attended and addressed the event, noting that AI empowerment will unlock new possibilities for environmental governance and industrial water conservation, and that the WateRobot AI Agent is an innovative achievement of deep integration between intelligence and water technology. Liu Donghua, Founder and Chief Architect of Zhenghe Island, delivered a speech proposing that the resource utilization of wastewater can find optimal solutions through AI, and that the widespread application and continuous upgrading of the WateRobot AI Agent can inject significant strength into achieving "Water Freedom" for industry, cities, and even the nation.The event invited AI expert Wei Kai, Director of the Artificial Intelligence Research Institute at the China Academy of Information and Communications Technology, to deliver a keynote speech on "Artificial Intelligence+ Policies and Industrial Practices". He pointed out that advancements in large language models have brought new paradigms to the development of AI technology, and the birth of the WateRobot AI Agent represents an important attempt of AI in the field of industrial water treatment.Subsequently, GreenTech officially launched the WateRobot AI Agent. Chairman Zhang Huichun proposed that using AI to replace human management of water plants can achieve industrial assembly line production, modular assembly, unmanned operation, and intelligent operation of water plants, replacing the traditional operational models of conventional engineered water plants. This leads to a 90% reduction in footprint, construction period, and operational staff, as well as a 50% reduction in Life Cycle Cost (LCC), ultimately enabling humanity to obtain Sustainable, Abundant, Reliable, and Affordable High-quality water (SARAH), achieving Water Freedom.(WateRobot AI Agent product interface)Wang Xiaoyu, General Manager of the Digital Technology Business Unit of GreenTech, further elaborated that the WateRobot AI Agent is an AI agent system capable of autonomous operation and completing target tasks. It not only incorporates GreenTech's self-developed process optimization forecasting and decision-making models but also integrates computer vision, auditory, infrared, and other perceptual AI models, as well as domestic large language inference models. Under the Online to Offline closed-loop logic, it directly delivers value to customers——safe, efficient, and optimally cost-operated unmanned water plants. The WateRobot AI Agent has already been applied in newater house water plant scenarios and is expected to expand to other water treatment plants, as well as industrial, agricultural, and municipal facilities, committed to enabling unmanned operation and innovative operational models across various fields.The event featured the unveiling ceremony of the "Artificial Intelligence Innovation Research Center" jointly established by GreenTech and Wuhan University. Zhang Liping, Deputy Director of the Industry-Academia-Research Cooperation Office of the Science and Technology Development Research Institute of Wuhan University, attended the unveiling and delivered a speech. Both parties will conduct in-depth technical research and industry applications focused on unmanned and intelligent operations. A roundtable dialogue on "AI + Industry" with the theme "AI's New Mission: Driving Industrial Restructuring and a Sustainable Future" was also held, where AI experts and various entrepreneurs discussed the application scenarios, value advantages, and future prospects of AI in the industrial field.GreenTech entered into strategic partnerships with the Finance Center for South-South Cooperation, Shanxi Xinzhou Economic Development Zone, CPIC Investment Management (H.K.), Wuhan Easy-Sight Technology Co.,Ltd., Green Technology (Shanghai) Agricultural Technology Co., Ltd., China Construction Eco-Development Co., Ltd., Beijing Boqi Electric Power Technology Co., Ltd., Beijing Zhenghe Island Information Technology Co., Ltd., and China Chemical Enterprise Management Association, among others, to jointly promote the application and promotion of the WateRobot AI Agent in the industry and various sectors domestically and internationally.The launch not only marked the debut of the WaterRobot AI Agent, a "new species" driving intelligent and green transformation in the industry but also envisioned the future of an intelligent water ecosystem——AI for Water Freedom. Through the innovative practices of GreenTech, the mission of "AI assisting industrial water savings and efficiency" has taken a solid step forward. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港，2025年9月23日 - (亞太商訊 via SeaPRwire.com) - 在功能飲料和健康飲品市場迅速成長的當下，國際品牌正通過產品創新與文化聯結爭奪新一代消費者。9月22日，IFBH Limited（「IFBH」，6603.HK）旗下品牌INNOCOCO正式推出兩款新品電解質水，並宣佈啟用亞洲超人氣偶像團體「時代少年團」作為其首位品牌代言人。新品發佈與代言人簽約的背後，折射出IFBH正在從單一椰子水品牌向多元產品矩陣拓展，加速打造第二增長曲線。持續豐富產品矩陣，夯實營收韌性長期以來，IFBH依託泰國優質原料與成熟供應鏈，以「if」椰子水和Innococo 100%椰子水在亞洲市場樹立了天然健康飲品標杆，深受消費者認可。按零售額計，IFBH已連續多年穩居中國內地椰子水飲料市場首位，同時也是全球椰子水飲料市場第二大公司。在穩固椰子水市場領先地位的基礎上，IFBH積極向其他飲料細分賽道拓展，主動開啟產品多元化升級進程。新品電解質水的發佈與品牌煥新，意味著INNOCOCO正從以往「真正椰子水的醇正口感，更健康」的品牌認知，轉型為引領新一代功能性飲料的品牌，面向更廣闊的市場需求。“這不僅僅是一次新品發佈，更是一次品牌煥新” IFBH Limited（INNOCOCO品牌產品製造商與經銷商）的首席執行官Pongsakorn Pongsak先生表示，“我們正從一個備受信賴的椰子水品牌，轉型成為當今活力一代的貼心夥伴。通過「時代少年團」擔任品牌代言人，我們將讓INNOCOCO比以往任何時候都更貼近年輕消費者。”新品電解質水在配方上注入真實椰子水，富含維生素B族並提供雙倍電解質，更快補水、更貼合運動與高能量場景，是對品牌基因的延伸與升級。同時，通過「時代少年團」這一亞洲超人氣偶像團體的代言，INNOCOCO不僅獲得廣泛的年輕消費群體關注，也在文化層面完成了與Z世代、Alpha世代的對話，為產品在上市初期即打下品牌勢能。從經營層面看，新產品線的加入，在強化IFBH核心業務優勢的同時，豐富了收入來源，為公司構建起 「核心產品穩基盤、創新產品拓增量」 的增長格局，進一步增強公司營收韌性，提升長期估值。產品運營成效顯著，強勁驅動資本市場表現在中國乃至亞太飲品市場品質化、多元化趨勢日益明顯的背景下，IFBH正以新品類、新代言和新渠道為支點，加速構建「產品創新+品牌賦能」的增長飛輪。INNOCOCO電解質水的推出和啟動「時代少年團」代言，標誌著IFBH在椰子水以外的功能性飲料領域邁出堅實一步。未來，隨著新品推廣、代言活動和渠道拓展逐步落地，IFBH有望在高端及功能性飲品賽道持續領跑，釋放更大的業績增長彈性。得益於公司經營成效的驅動，公司最近在資本市場上的表現也十分搶眼。近期，公司股價呈現強勁的上行態勢，一度從最低點30港元，最高時成功觸及40.26港元，漲幅相當可觀。事實上，IFBH在產品運營與市方面的成效已經在中期業績得到充分驗證。2025年上半年，IFBH取得收益 94.5百萬美元，同比增加 31.5%，增速明顯跑贏行業平均水平；母公司擁有人應占溢利 1497.6 萬美元；經調整溢利淨額 1890 萬美元，同比增加 13.9%。而新品發佈與「時代少年團」代言等積極動作，有望進一步點燃資本市場對公司未來增長的憧憬。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Sep 23, 2025 - (ACN Newswire via SeaPRwire.com) – Nissin Foods Company Limited (“Nissin Foods”, together with its subsidiaries, the “Group”; Stock code: 1475) is pleased to announce that the Group has entered into contracts for the land use rights of two strategically located parcels of land (the “Land Parcels”) in Zhuhai.Located in the Jinwan District of Zhuhai City, Guangdong Province, the Land Parcels were sold by the Zhuhai Natural Resources Bureau, a government authority responsible for managing land resources. The total consideration for the land is RMB30.68 million, covering a total land area of approximately 58,487 square meters. Nissin Foods plans to invest over RMB240 million to acquire the land, construct new facilities, and install cutting-edge automated production lines. Nissin Foods is committed to providing consumers with high-quality yet affordable food products. Incorporated with advanced automation and labour-saving technologies, the new factory will enhance production capacity and improve efficiency by reducing operational downtime. These initiatives are part of the Group’s commitment to sustainable growth, enabling it to respond flexibly to market changes and keep pace with growing consumer demand for the Group’s premium products. Strategically located in the Greater Bay Area, the new factory will create operational synergies with the current adjacent facilities of the Group.Mr. Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, “Despite global economic uncertainties, Mainland China’s consumer market maintained steady recovery in the first half of 2025, driven by a series of government policies aimed at stimulating consumption and expanding domestic demand. Consequently, the Group’s revenue in Mainland China rose by 9.4% to HK$1,221.9 million in the same period.“This land acquisition aligns perfectly with the company’s strategic goals and supports its ongoing growth. The new land and facilities will help maintain a steady supply of quality products while meeting the anticipated growth in sales. This is expected to inject new momentum into the Group’s operational development and long-term growth prospects, thereby enhancing its overall income and profitability.”For more information, please refer to the announcement on the Hong Kong Stock Exchange website: www1.hkexnews.hk/listedco/listconews/sehk/2025/0911/2025091100394.pdfAbout Nissin Foods Company LimitedNissin Foods Company Limited ("Nissin Foods”, together with its subsidiaries, the “Group”; Stock code: 1475) is a renowned food company in Hong Kong and Mainland China, with a diversified portfolio of well-known and highly popular brands, primarily focusing on the premium instant noodle segment. The Group officially established its presence in Hong Kong in 1984 and is the largest instant noodle company in Hong Kong. The Group primarily manufactures and sells instant noodles, high-quality frozen food products, including frozen dim sum and frozen noodles, and also sells and distributes other food and beverage products, including retort pouches, snacks, mineral water, sauce and vegetable products under its two core corporate brands, namely “NISSIN ” and “DOLL” together with a diversified portfolio of iconic household premium brands. The Group’s five flagship product brands, namely “Cup Noodles”, “Demae Iccho”, “Doll Instant Noodle”, “Doll Dim Sum ” and “Fuku” are also among the most popular choices in their respective food product categories in Hong Kong. In the Mainland China market, the Group has introduced technology innovation through the “ECO Cup” concept and primarily focuses its sales efforts in first-and second-tier cities. In addition, Nissin Foods operates business in other regions including Vietnam, Taiwan, Korea and Australia markets.Nissin Foods is currently a constituent of five Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Composite SmallCap Index, Hang Seng Composite Industry Index - Consumer Staples, Hang Seng SCHK Consumption Index and Hang Seng SCHK Food and Drink Index. Nissin Foods is eligible for trading under Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect. For more information, please visit www.nissingroup.com.hk. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港，2025年9月23日 - (亞太商訊 via SeaPRwire.com) - 日清食品有限公司（「日清食品」或「公司」，連同其附屬公司統稱「集團」；股份代號：1475）欣然宣布，集團已就位於珠海的兩幅地塊（「地塊」）的土地使用權簽訂了合同。該等地塊位於廣東省珠海市金灣區，由負責管理珠海土地資源的政府機構珠海市自然資源局出售。地塊收購的總代價為人民幣30.68百萬元，總土地面積約為58,487平方米。集團擬投資超過人民幣240百萬元，用於收購該等地塊、建設新廠房以及安裝先進的自動化生產線。日清食品致力為消費者提供優質且價格實惠的食品。新工廠採用先進的自動化和節省人力的技術，將能提升産能，並通過減少停機時間來提高生產效率。這些措施是集團實踐可持續增長的重要部分，使其能夠靈活應對市場變化，同時滿足消費者對集團高端産品日益增長的需求。新工廠座落於粵港澳大灣區，將與集團現有鄰近設施形成營運協同效應。日清食品執行董事、董事長兼首席執行官安藤清隆先生表示：「儘管全球經濟形勢充滿不確定性，但受一系列刺激消費、擴大內需的政府政策所驅動下，中國內地的消費市場於2025年上半年持續穩定復甦。集團同期的中國內地業務收入因而增長9.4%至1,221.9百萬港元。「是次土地收購與公司的策略目標完美契合，支撑其持續增長。新增土地和設施將有助於維持優質產品的穩定供應，同時滿足預期的銷售成長。預計這將為集團的營運發展和長期成長前景注入新動力，從而提升集團的整體收入及盈利能力。」如欲了解更多信息，請參閱香港聯合交易所網站上的公告：www1.hkexnews.hk/listedco/listconews/sehk/2025/0911/2025091100395_c.pdf有關日清食品有限公司日清食品有限公司（「日清食品」，連同其附屬公司統稱「集團」；股份代號：1475）為一間在中國内地及香港知名的食品公司，主要專營優質即食麵市場，旗下眾多品牌不僅知名度高，且廣受顧客喜愛。集團於1984年正式於香港設立營業據點並為香港最大的即食麵公司。集團主要生產及銷售兩個核心企業品牌「日清」及「公仔」，以及多元化的家庭食品品牌組合，出品具標誌性和優質的即食麵、優質冷凍食品（包括冷凍點心及冷凍麵條）並銷售和分銷其他食品及飲料產品（包括蒸煮袋裝產品、零食、礦泉水、醬料及蔬菜產品）。集團五個旗艦品牌「合味道」、「出前一丁」、「公仔麵」、「公仔點心」及「福」在香港亦是其各自食品類別中最受歡迎的選擇。中國内地市場方面，集團以創新技術推出「ECO杯」概念，銷售活動主要集中在中國内地的一線及二線城市。此外，日清食品在其他地區開展業務，包括越南、台灣、韓國及澳洲市場。日清食品被納入5項恒生指數，包括恒生綜合指數、恒生綜合小型股指數、恒生綜合行業指數-必需性消費、恒生港股通消費行業指數和恒生港股通食品飲料消費指數。日清食品現可通過滬港通及深港通下港股通進行交易。詳情請瀏覽www.nissingroup.com.hk。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - September 22, 2025) - Gold-copper explorer and hybrid project generator Kincora Copper Limited (ASX: KCC) (TSXV: KCC) (Kincora or the Company) is pleased to announce that it has resecured the full rights of its Mongolian c0pper-gold portfolio following Orbminco Limited's (ASX: OB1) (formerly known as Woomera Mining Limited) withdrawal from the September 2024 Earn-In Agreement as it now focuses on its Australian gold exploration.Assets within the portfolio include:a large Mineral Resource Estimate and Exploration Target reported under the JORC Code by Resilience Mining Mongolia Limited 1 for the West Kasulu prospect, which includes a small portion of one of three extensive, from surface and underexplored copper-gold intrusive complexes (the majority hosted on an existing 30-year mining license);a year-round field camp; and,a proprietary Mongolia wide project generation database.Further details are provided in an Appendix to this release.This development comes at a time of various notable positive developments highlighting the potential of Mongolian's resource sector and the Bronze Fox copper-gold project. These include:Xanadu Mines and its flagship Kharmagtai copper-gold project's recent A$160-million takeover by Bastion Mining Pte. Ltd,Erdene Resource Development's first gold pour at its greenfield Bayan Khundii project,construction of the privately held Tsagaan Suvarga copper-molybdenum project, and,the Oyu Tolgoi copper-gold project being on track to be the world's fourth largest copper mine by 2030.With Kincora now controlling 100% ownership, the Company will move forward to build on existing and new interest in the project.Kincora intends to consider a range of options, including focused self-funded exploration, third party investment and other corporate initiatives. Near term value add activities may include the potential submission for a second mining license at the Bronze Fox project and fresh mining studies relating to the existing oxide resource reflecting recent shifting in commodity prices.Further market updates will be provided following any material development arising to the Company's Mongolian asset portfolio.This announcement has been authorised for release by the Board of Kincora Copper Limited (ARBN 645 457 763)For further information please contact: Kincora Copper Limited Sam Spring, President and Chief Executive Officer sam.spring@kincoracopper.com or +61431 329 345AppendixKincora's Mongolian asset portfolio includes a 100% interest in one of the largest land positions and porphyry complexes in the Southern Gobi copper-gold belt, a region which is one of the world's most rapidly emerging sources of copper supply and infrastructure development.The Company's Mongolian portfolio assets include:Bronze Fox mining license (the eastern license of the Bronze Fox project),Tourmaline Hills exploration license (the western license of the Bronze Fox project),White Pearl field camp (year-round facility), and,one of (if not) the largest project generation databases for Mongolia.In July 2022, the Company announced a maiden Inferred Mineral Resource Estimate (MRE) and updated Exploration Target for the West Kasulu prospect within the Bronze Fox project reported under the JORC code and prepared by Resilience Mining Mongolia Limited 1. Both the MRE and Exploration Target are open in all directions 1.The MRE 1 hosts a from surface oxide component with previous metallurgical analysis and desktop studies supporting the potential for a low capex SX-EW (solvent extraction-electrowinning) development project producing a finished copper cathode product.The majority of the MRE and Exploration Target 1 are situated within the existing Bronze Fox mining licence with the balance being on the adjoining Tourmaline Hills exploration licence (collectively the Bronze Fox project).With Kincora now retaining 100% ownership and optionality around adding value to the asset base, the Company intends to consider a range of options including the potential for a near term submission for a second mining license which would provide mining license coverage across the full project and be a major milestone unlocking the potential for a SX-EW development project. Kincora will consider fresh mining studies relating to the existing oxide resource reflecting recent shifting in commodity prices.The West Kasulu prospect is hosted within a small portion of the much larger mineralised Bronze Fox Intrusive Complex, which is one of three so far identified underexplored, near surface and large porphyry complexes at the wider Bronze Fox project.2024 field season activities undertaken by Orbminco Limited included predominately infill drilling, required to support conversion of the existing Tourmaline Hills exploration license to a mining license, plus one deep diamond drill hole 2. The 2025 field season sampling and mapping activities further confirmed and expanded the potential for a higher-grade extension to the current MRE envelope 1, which remains open 3. More recent geophysical programs comprised of Induced Polarisation (IP) and gravity surveys have also been completed reconfirming existing targets and identified additional targets for further review 4.2025 field sampling and geophysical programs have also been undertaken at the Shuteen North target, which hosts extensive sub-cropping copper mineralisation and multiple intrusive systems 3 4. The Shuteen North target has never been previously drilled and is interpreted to be associated with the Shuteen lithocap, the largest lithocap in the Southern Gobi. The importance of this conceptual geological setting is significant given the lithocap at the Oyu Tolgoi project was an important early-stage exploration marker and the relative size of the Shuteen lithocap relatively to Oyu Tolgoi.The Company continues to defend a tax assessment that was relied upon to complete a merger in 2016, with the Mongolian Supreme Court scheduled to hear this case again in the next month.Please refer to Kincora's website and contact the Company for further details.Footnotes1 The Mineral Resource Estimate (MRE) and Exploration Target have been prepared by independent consultant DG & JG Larsen Consulting Pty Ltd and are reported in accordance with the Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves 2012 (JORC Code) and is not based on Canadian Institute of Mining, Metallurgy and Petroleum (CIM) definitions, and as a result the estimate is not recognized under National Instrument 43-101 of the Canadian Securities Administrators (NI 43-101).The MRE and Exploration Target were commissioned and paid for by Resilience Mining Mongolia Limited, an unrelated party, meeting a condition precedent from a Joint Venture and Acquisition Agreement, and subsequent extension agreement, that was subsequently terminated by Kincora. The MRE and Exploration Target were based on data and geological information supplied by Kincora and Resilience Mining Mongolia Limited.The MRE and Exploration Target were reviewed by Kincora's geological staff under the supervision of Paul Cromie (BSc Hons. M.Sc. Economic Geology, PhD, member of the Australian Institute of Mining and Metallurgy and Society of Economic Geologists), then Exploration Manager Australia, who was the Qualified Persons for the purpose of NI 43-101.In 2022, Kincora retained a 100% interest in the project, data and reports pertaining to the MRE and Exploration Target from Resilience Mining Mongolia Limited (see the July 8, 2022, release "Kincora provides corporate update for Mongolian portfolio" for further details).In September 2024, Kincora executed a definitive agreement with Orbminco Limited's (formerly Woomera Mining Limited) to provide certain rights to the Mongolian project. Under the Earn-In and Joint Venture Agreement with Kincora multiple phases of exploration were undertaken by Orbminco Limited, including:4Q'2024 drilling program: a sixteen hole for 2,516 metre drilling program was completed designed to infill and extend the existing MRE with results that "confirm expansion and higher-grade potential of the West Kasulu resource" 2.1Q'2025 mapping and surface sampling program: the program "validated historic sampling and confirm a high-grade, copper-gold extension structure at the West Kasulu prospect which is open and trends northwest beneath shallow cover". Orbminco noted the "trend remains largely undrilled and that IP and gravity surveys are proposed to facilitate follow up drilling". At the Shuteen North prospect, located 10km southwest of the West Kasulu MRE, "limited previous exploration has recorded extensive sub-cropping copper mineralisation and multiple phase intrusive systems associated with strong mineral alteration, which has been confirmed during the recent mapping" 3.3Q'2025 geophysical program: a "large geophysical survey" included induced polarisation (IP) and gravity survey and followed up the 1Q'2025 mapping and surface sampling program. "Several IP anomalies have been identified to the west of the current resource and at Shuteen North. The results of the completed IP and gravity surveys have reconfirmed the existing targets and identified additional targets for further review" 4.In accordance with the Earn-In and Joint Venture Agreement, Orbminco Limited will within 60 days following the date of effective termination deliver all technical data obtained to Kincora.The Company is not aware of any information otherwise which materially affects the information included in the announcement referred to above and, in the care of the MRE and Exploration Target, all material assumptions and technical parameters underpinning the estimates in that announcement continue to apply.For further details relating to the Mongolian licenses please refer to the Company's website (www.kincoracopper.com) and ASX listing prospectus, including the Mining Associates Technical Export Report (February 25, 2021).References1 Further details and technical disclosures included in the July 26, 2022, Kincora Copper press release "Mineral resource and updated exploration target for Bronze Fox". 2 Further details and technical disclosures included in the January 14, 2025, Orbminco Limited press release "Drilling Results for Bronze Fox Copper-Gold Project". 3 Further details and technical disclosures included in the March 26, 2025, Orbminco Limited press release "High grade copper-gold potential confirmed at Bronze Fox"4 Further details and technical disclosures included in the August 15, 2025, Orbminco Limited press release "Update on Mongolian Operations".Kincora Copper LimitedExecutive office400 - 837 West Hastings Street Vancouver, BC V6C 3N6, Canada Tel: 1.604.283.1722 Subsidiary office AustraliaC/- JM Corporate ServicesLevel 6, 350 Collins Street Melbourne, VIC, Australia 3000Forward-Looking StatementsCertain information regarding Kincora contained herein may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements may include estimates, plans, expectations, opinions, forecasts, projections, guidance or other statements that are not statements of fact. Although Kincora believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Kincora cautions that actual performance will be affected by a number of factors, most of which are beyond its control, and that future events and results may vary substantially from what Kincora currently foresees. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration results, continued availability of capital and financing and general economic, market or business conditions. The forward-looking statements are expressly qualified in their entirety by this cautionary statement. The information contained herein is stated as of the current date and is subject to change after that date. Kincora does not assume the obligation to revise or update these forward-looking statements, except as may be required under applicable securities laws.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) or the Australian Securities Exchange accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/267334 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com